Cancer Nanotheranostics: What Have We Learned So Far? (Record no. 67772)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 04936naaaa2200397uu 4500 |
| 001 - CONTROL NUMBER | |
| control field | https://directory.doabooks.org/handle/20.500.12854/42645 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20220220052548.0 |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 978-2-88919-776-7 |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 9782889197767 |
| 024 7# - OTHER STANDARD IDENTIFIER | |
| Standard number or code | 10.3389/978-2-88919-776-7 |
| Terms of availability | doi |
| 041 0# - LANGUAGE CODE | |
| Language code of text/sound track or separate title | English |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Pedro Viana Baptista |
| Relationship | auth |
| 245 10 - TITLE STATEMENT | |
| Title | Cancer Nanotheranostics: What Have We Learned So Far? |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Name of publisher, distributor, etc. | Frontiers Media SA |
| Date of publication, distribution, etc. | 2016 |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 1 electronic resource (128 p.) |
| 506 0# - RESTRICTIONS ON ACCESS NOTE | |
| Terms governing access | Open Access |
| Source of term | star |
| Standardized terminology for access restriction | Unrestricted online access |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | After a quarter of century of rapid technological advances, research has revealed the complexity of cancer, a disease intimately related to the dynamic transformation of the genome. However, the full understanding of the molecular onset of this disease is still far from achieved and the search for mechanisms of treatment will follow closely. It is here that Nanotechnology enters the fray offering a wealth of tools to diagnose and treat cancer. In fact, the National Cancer Institute predicts that over the next years, nanotechnology will result in important advances in early detection, molecular imaging, targeted and multifunctional therapeutics, prevention and control of cancer. Nanotechnology offers numerous tools to diagnose and treat cancer, such as new imaging agents, multifunctional devices capable of overcome biological barriers to deliver therapeutic agents directly to cells and tissues involved in cancer growth and metastasis, and devices capable of predicting molecular changes to prevent action against precancerous cells. Nanomaterials-based delivery systems in Theranostics (Diagnostics & Therapy) provide better penetration of therapeutic and diagnostic substances within the body at a reduced risk in comparison to conventional therapies. At the present time, there is a growing need to enhance the capability of theranostics procedures where nanomaterials-based sensors may provide for the simultaneous detection of several gene-associated conditions and nanodevices with the ability to monitor real-time drug action. These innovative multifunctional nanocarriers for cancer theranostics may allow the development of diagnostics systems such as colorimetric and immunoassays, and in therapy approaches through gene therapy, drug delivery and tumor targeting systems in cancer. Some of the thousands and thousands of published nanosystems so far will most likely revolutionize our understanding of biological mechanisms and push forward the clinical practice through their integration in future diagnostics platforms. Nevertheless, despite the significant efforts towards the use of nanomaterials in biologically relevant research, more in vivo studies are needed to assess the applicability of these materials as delivery agents. In fact, only a few went through feasible clinical trials. Nanomaterials have to serve as the norm rather than an exception in the future conventional cancer treatments. Future in vivo work will need to carefully consider the correct choice of chemical modifications to incorporate into the multifunctional nanocarriers to avoid activation off-target, side effects and toxicity. Moreover the majority of studies on nanomaterials do not consider the final application to guide the design of nanomaterial. Instead, the focus is predominantly on engineering materials with specific physical or chemical properties. It is imperative to learn how advances in nanosystem’s capabilities are being used to identify new diagnostic and therapy tools driving the development of personalized medicine in oncology; discover how integrating cancer research and nanotechnology modeling can help patient diagnosis and treatment; recognize how to translate nanotheranostics data into an actionable clinical strategy; discuss with industry leaders how nanotheranostics is evolving and what the impact is on current research efforts; and last but not least, learn what approaches are proving fruitful in turning promising clinical data into treatment realities. |
| 540 ## - TERMS GOVERNING USE AND REPRODUCTION NOTE | |
| Terms governing use and reproduction | Creative Commons |
| Use and reproduction rights | https://creativecommons.org/licenses/by/4.0/ |
| Source of term | cc |
| -- | https://creativecommons.org/licenses/by/4.0/ |
| 546 ## - LANGUAGE NOTE | |
| Language note | English |
| 653 ## - INDEX TERM--UNCONTROLLED | |
| Uncontrolled term | Nanoparticles |
| 653 ## - INDEX TERM--UNCONTROLLED | |
| Uncontrolled term | Gene Therapy |
| 653 ## - INDEX TERM--UNCONTROLLED | |
| Uncontrolled term | Immunotherapy |
| 653 ## - INDEX TERM--UNCONTROLLED | |
| Uncontrolled term | bioimaging |
| 653 ## - INDEX TERM--UNCONTROLLED | |
| Uncontrolled term | theranostics |
| 653 ## - INDEX TERM--UNCONTROLLED | |
| Uncontrolled term | nanomaterials |
| 653 ## - INDEX TERM--UNCONTROLLED | |
| Uncontrolled term | Drug delivery |
| 653 ## - INDEX TERM--UNCONTROLLED | |
| Uncontrolled term | Nanomedicine |
| 653 ## - INDEX TERM--UNCONTROLLED | |
| Uncontrolled term | Cancer |
| 653 ## - INDEX TERM--UNCONTROLLED | |
| Uncontrolled term | Phototherapy |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Jesus M. De La Fuente |
| Relationship | auth |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Joao Conde |
| Relationship | auth |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Furong Tian |
| Relationship | auth |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Host name | www.oapen.org |
| Uniform Resource Identifier | <a href="http://journal.frontiersin.org/researchtopic/2709/cancer-nanotheranostics-what-have-we-learned-so-far">http://journal.frontiersin.org/researchtopic/2709/cancer-nanotheranostics-what-have-we-learned-so-far</a> |
| Access status | 0 |
| Public note | DOAB: download the publication |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Host name | www.oapen.org |
| Uniform Resource Identifier | <a href="https://directory.doabooks.org/handle/20.500.12854/42645">https://directory.doabooks.org/handle/20.500.12854/42645</a> |
| Access status | 0 |
| Public note | DOAB: description of the publication |
No items available.